SCHEMBL13266248

SCHEMBL13266248

CCCC(C)(Cl)c1ccc(C(=O)c2ccc(Oc3cccc4c(OC(C)(CCC)c5ccc(C(=O)c6ccc(Cl)cc6)cc5)cccc34)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 6/20 0.40
▸ PPARG P37231 3/20 0.40
▸ FABP2 P12104 1/20 0.40
▸ SLC22A12 Q96S37 1/20 0.40
▸ ELANE P08246 2/20 0.38
▸ MCL1 Q07820 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MAPT P10636 3/20 0.36
▸ HPGD P15428 3/20 0.36
▸ ATM Q13315 2/20 0.36
▸ ABCB11 O95342 2/20 0.36
▸ CYP1A2 P05177 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ TSHR P16473 2/20 0.36
▸ HTR2A P28223 2/20 0.36
▸ PMP22 Q01453 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13266244 0.92 MAPT (0.39) PPARAPPARGFABP2SLC22A12ELANE
SCHEMBL13602275 0.87 MCL1 (0.35) PPARAMCL1KMT2AMAPTHPGD
SCHEMBL13266249 0.83 MCL1 (0.35) MCL1MEN1KMT2AMAPTCYP3A4
SCHEMBL13266188 0.82 MCL1 (0.39) ELANEMCL1MEN1KMT2AMAPT
SCHEMBL13602273 0.79 MCL1 (0.35) MCL1KMT2AMAPTSMN1; SMN2TDP1
SCHEMBL13082581 0.78 MCL1 (0.40) ELANEMCL1MEN1KMT2AMAPT
SCHEMBL12464121 0.77 ELANE (0.41) PPARAPPARGELANEMCL1MAPT
SCHEMBL13082664 0.77 PPARA (0.40) PPARAPPARGFABP2SLC22A12ELANE
SCHEMBL822946 0.77 HPGD (0.54) PPARAPPARGFABP2SLC22A12ELANE
SCHEMBL13082580 0.74 MCL1 (0.40) PPARAELANEMCL1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293905-B2 Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-23 — — US disclosed
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-07-22 — — US disclosed
US-20090326188-A1 Method for producing polyarylene SUMITOMO CHEMICAL COMPANY, LIMITED 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX C9, C5, AP2M1 PPARA 4231/4885PPARG 4090/4885FABP2 4210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback